tailieunhanh - Báo cáo y học: " New approaches to the modulation of inflammatory processes in airway disease models"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:New approaches to the modulation of inflammatory processes in airway disease models. | Available online http content 2 5 E003 Meeting report New approaches to the modulation of inflammatory processes in airway disease models ATS 2001 May 18-23 San Francisco David J Hele Respiratory Pharmacology Group Cardiothoracic Surgery Imperial College School of Medicine National Heart and Lung Institute London UK Correspondence David J Hele Respiratory Pharmacology Group Cardiothoracic Surgery Imperial College School of Medicine National Heart and Lung Institute Dovehouse Street London SW3 6LY UK. Tel 44 0 207 352 8121 Ext. 3042 fax 0207-351-8126 e-mail Received 1 June 2001 Revisions requested 13 June 2001 Revisions received 13 June 2001 Accepted 14 June 2001 Published 3 July 2001 Respir Res 2001 2 E003 2001 BioMed Central Ltd Print ISSN 1465-9921 Online ISSN 1465-993X Abstract The 97th American Thoracic Society meeting proved to be an excellent meeting providing a wealth of new information on inflammatory diseases of the airways. Once again there appeared to be an increased emphasis on chronic obstructive pulmonary disease COPD with most of the major drug companies concentrating a large part of their efforts in this field. An assessment of the new British Thoracic Society guidelines which are designed to promote better management of COPD was also presented at the meeting. Potential new treatments for inflammatory diseases of the airways including COPD were described ranging from phase III trial data with GlaxoSmithKline s PDE4 inhibitor Cilomilast Ariflo to the development of AstraZeneca s novel dual dopamine D2-receptor P2-adrenoreceptor agonist Viozan . Of particular interest was Byk Gulden s Ciclesonide a new corticosteroid with equivalent efficacy to the market leaders but with an improved safety profile. The same company also presented data on their PDE4 inhibitor Roflumilast which is now in phase II III. Bayer presented data on their PDE4 inhibitor BAY 19-8004 in a smoking animal model and claimed greater .